LAM Announces Second Commercial Order From Chinese Pharma

LAM Pharmaceutical, a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, has received a second order for IPM Wound Gel from Sinopharm Group, a subsidiary of one of China's largest pharmaceutical companies. The second order from LAM's distribution partner totals $80,000, matching the size of the first order placed in December 2004.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18819720&full=1)